<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Apogee Therapeutics, Inc. Common Stock — News on 6ix</title>
<link>https://6ix.com/company/apogee-therapeutics-inc-common-stock</link>
<description>Latest news and press releases for Apogee Therapeutics, Inc. Common Stock on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 26 Mar 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/apogee-therapeutics-inc-common-stock" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683546ef78dffbe2df0e3318.webp</url>
<title>Apogee Therapeutics, Inc. Common Stock</title>
<link>https://6ix.com/company/apogee-therapeutics-inc-common-stock</link>
</image>
<item>
<title>Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $403 Million</title>
<link>https://6ix.com/company/apogee-therapeutics-inc-common-stock/news/apogee-therapeutics-inc-announces-closing-of-public-offering-and-full-exercise-of-the-underwriters-option-to-purchase-additional-shares-for-gross-proceeds-of-dollar403-million</link>
<guid isPermaLink="true">https://6ix.com/company/apogee-therapeutics-inc-common-stock/news/apogee-therapeutics-inc-announces-closing-of-public-offering-and-full-exercise-of-the-underwriters-option-to-purchase-additional-shares-for-gross-proceeds-of-dollar403-million</guid>
<pubDate>Thu, 26 Mar 2026 04:00:00 GMT</pubDate>
<description>SAN FRANCISCO and BOSTON, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing</description>
</item>
<item>
<title>Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering</title>
<link>https://6ix.com/company/apogee-therapeutics-inc-common-stock/news/apogee-therapeutics-inc-announces-pricing-of-dollar350-million-underwritten-public-offering</link>
<guid isPermaLink="true">https://6ix.com/company/apogee-therapeutics-inc-common-stock/news/apogee-therapeutics-inc-announces-pricing-of-dollar350-million-underwritten-public-offering</guid>
<pubDate>Tue, 24 Mar 2026 04:00:00 GMT</pubDate>
<description>SAN FRANCISCO and BOSTON, March 24, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing</description>
</item>
<item>
<title>Apogee Therapeutics Announces Positive Phase 2 Part A 52-Week Data of Zumilokibart (APG777), Demonstrating Maintenance and Deepening of Responses with Every 3- and 6-Month Dosing in Moderate-to-Severe Atopic Dermatitis</title>
<link>https://6ix.com/company/apogee-therapeutics-inc-common-stock/news/apogee-therapeutics-announces-positive-phase-2-part-a-52-week-data-of-zumilokibart-apg777-demonstrating-maintenance-and-deepening-of-responses-with-every-3-and-6-month-dosing-in-moderate-to-severe-atopic-dermatitis</link>
<guid isPermaLink="true">https://6ix.com/company/apogee-therapeutics-inc-common-stock/news/apogee-therapeutics-announces-positive-phase-2-part-a-52-week-data-of-zumilokibart-apg777-demonstrating-maintenance-and-deepening-of-responses-with-every-3-and-6-month-dosing-in-moderate-to-severe-atopic-dermatitis</guid>
<pubDate>Mon, 23 Mar 2026 04:00:00 GMT</pubDate>
<description>APEX Part A data demonstrated durable maintenance of response at 52-weeks for every 3- and 6-months dosing, respectively, including:- 75% and 85% patients</description>
</item>
<item>
<title>Apogee Therapeutics, Inc. Announces Proposed $300 Million Underwritten Public Offering</title>
<link>https://6ix.com/company/apogee-therapeutics-inc-common-stock/news/apogee-therapeutics-inc-announces-proposed-dollar300-million-underwritten-public-offering</link>
<guid isPermaLink="true">https://6ix.com/company/apogee-therapeutics-inc-common-stock/news/apogee-therapeutics-inc-announces-proposed-dollar300-million-underwritten-public-offering</guid>
<pubDate>Mon, 23 Mar 2026 04:00:00 GMT</pubDate>
<description>SAN FRANCISCO and BOSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing</description>
</item>
<item>
<title>Apogee Therapeutics to Host Conference Call to Report Part A 52-Week Data from the Phase 2 APEX Trial of Zumilokibart (APG777) in Patients with Moderate-to-Severe Atopic Dermatitis on March 23, 2026</title>
<link>https://6ix.com/company/apogee-therapeutics-inc-common-stock/news/apogee-therapeutics-to-host-conference-call-to-report-part-a-52-week-data-from-the-phase-2-apex-trial-of-zumilokibart-apg777-in-patients-with-moderate-to-severe-atopic-dermatitis-on-march-23-2026</link>
<guid isPermaLink="true">https://6ix.com/company/apogee-therapeutics-inc-common-stock/news/apogee-therapeutics-to-host-conference-call-to-report-part-a-52-week-data-from-the-phase-2-apex-trial-of-zumilokibart-apg777-in-patients-with-moderate-to-severe-atopic-dermatitis-on-march-23-2026</guid>
<pubDate>Sun, 22 Mar 2026 04:00:00 GMT</pubDate>
<description>Webcast to be held Monday, March 23rd at 8:00 a.m. ET SAN FRANCISCO and BOSTON, March 22, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a</description>
</item>
<item>
<title>Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/apogee-therapeutics-inc-common-stock/news/apogee-therapeutics-provides-pipeline-progress-and-reports-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/apogee-therapeutics-inc-common-stock/news/apogee-therapeutics-provides-pipeline-progress-and-reports-full-year-2025-financial-results</guid>
<pubDate>Mon, 02 Mar 2026 05:00:00 GMT</pubDate>
<description>Zumilokibart (APG777) trials continue to advance in atopic dermatitis (AD) with plans for expansion indications underway:- APEX Phase 2 Part A 52-week data</description>
</item>
<item>
<title>Apogee Therapeutics to Participate in Upcoming March Conferences</title>
<link>https://6ix.com/company/apogee-therapeutics-inc-common-stock/news/apogee-therapeutics-to-participate-in-upcoming-march-conferences</link>
<guid isPermaLink="true">https://6ix.com/company/apogee-therapeutics-inc-common-stock/news/apogee-therapeutics-to-participate-in-upcoming-march-conferences</guid>
<pubDate>Tue, 24 Feb 2026 12:30:00 GMT</pubDate>
<description>SAN FRANCISCO and BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026, at 9:10 a.m. E.T. Management will also attend the UBS Biotech Summit Miami, Catalyst for Change on Monday, March 9, 2026, and the Jefferies Biotech on the Beach Summit on Tuesday, March 10, 2026. A live and archived webcast of the fireside c</description>
</item>
<item>
<title>Apogee Therapeutics to Participate at the Guggenheim Emerging Outlook: Biotech Summit 2026</title>
<link>https://6ix.com/company/apogee-therapeutics-inc-common-stock/news/apogee-therapeutics-participate-guggenheim-emerging-outlook-biotech-summit-2026-2026</link>
<guid isPermaLink="true">https://6ix.com/company/apogee-therapeutics-inc-common-stock/news/apogee-therapeutics-participate-guggenheim-emerging-outlook-biotech-summit-2026-2026</guid>
<pubDate>Thu, 05 Feb 2026 05:00:00 GMT</pubDate>
<description>SAN FRANCISCO and BOSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), today announced that members of management will</description>
</item>
<item>
<title>Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and Outlook</title>
<link>https://6ix.com/company/apogee-therapeutics-inc-common-stock/news/apogee-therapeutics-announces-positive-interim-results-phase-1b-trial-zumilokibart</link>
<guid isPermaLink="true">https://6ix.com/company/apogee-therapeutics-inc-common-stock/news/apogee-therapeutics-announces-positive-interim-results-phase-1b-trial-zumilokibart</guid>
<pubDate>Tue, 06 Jan 2026 05:00:00 GMT</pubDate>
<description>Phase 1b interim results of zumilokibart (APG777) in asthma demonstrated rapid and durable suppression of FeNO (key biomarker of Type 2 inflammation) through</description>
</item>
<item>
<title>Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1b Trial of APG777 in Patients with Mild-to-Moderate Asthma and 2026 Anticipated Milestones on January 6, 2026</title>
<link>https://6ix.com/company/apogee-therapeutics-inc-common-stock/news/apogee-therapeutics-host-conference-call-report-interim-results-phase-1b-trial-apg777</link>
<guid isPermaLink="true">https://6ix.com/company/apogee-therapeutics-inc-common-stock/news/apogee-therapeutics-host-conference-call-report-interim-results-phase-1b-trial-apg777</guid>
<pubDate>Mon, 05 Jan 2026 05:00:00 GMT</pubDate>
<description>Webcast to be held Tuesday, January 6th at 8:00 a.m. ET SAN FRANCISCO and BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE),</description>
</item>
<item>
<title>Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/apogee-therapeutics-inc-common-stock/news/apogee-therapeutics-provides-pipeline-progress-and-reports-third-quarter-2025</link>
<guid isPermaLink="true">https://6ix.com/company/apogee-therapeutics-inc-common-stock/news/apogee-therapeutics-provides-pipeline-progress-and-reports-third-quarter-2025</guid>
<pubDate>Mon, 10 Nov 2025 05:00:00 GMT</pubDate>
<description>Pipeline programs continue to advance, with four clinical data readouts anticipated in 2026; APG777 trial readout timelines accelerated, with Phase 1b in</description>
</item>
<item>
<title>Apogee Therapeutics Announces Positive Interim Phase 1 Results from Healthy Volunteer Trial of APG333, its Novel Half-Life Extended TSLP Antibody</title>
<link>https://6ix.com/company/apogee-therapeutics-inc-common-stock/news/apogee-therapeutics-announces-positive-interim-phase-1-results-healthy-volunteer</link>
<guid isPermaLink="true">https://6ix.com/company/apogee-therapeutics-inc-common-stock/news/apogee-therapeutics-announces-positive-interim-phase-1-results-healthy-volunteer</guid>
<pubDate>Mon, 10 Nov 2025 05:00:00 GMT</pubDate>
<description>Interim Phase 1 results for APG333 exceeded trial objectives, demonstrated a half-life of approximately 55 days, and suppressed key biomarkers for 6 months</description>
</item>
<item>
<title>Apogee Therapeutics to Participate in Upcoming Conferences</title>
<link>https://6ix.com/company/apogee-therapeutics-inc-common-stock/news/apogee-therapeutics-participate-upcoming-conferences-2025-11-03</link>
<guid isPermaLink="true">https://6ix.com/company/apogee-therapeutics-inc-common-stock/news/apogee-therapeutics-participate-upcoming-conferences-2025-11-03</guid>
<pubDate>Mon, 03 Nov 2025 05:00:00 GMT</pubDate>
<description>SAN FRANCISCO and BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), today announced that members of management will</description>
</item>
<item>
<title>Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $345 Million</title>
<link>https://6ix.com/company/apogee-therapeutics-inc-common-stock/news/apogee-therapeutics-inc-announces-closing-public-offering-and-full-exercise</link>
<guid isPermaLink="true">https://6ix.com/company/apogee-therapeutics-inc-common-stock/news/apogee-therapeutics-inc-announces-closing-public-offering-and-full-exercise</guid>
<pubDate>Fri, 10 Oct 2025 04:00:00 GMT</pubDate>
<description>SAN FRANCISCO and BOSTON, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing</description>
</item>
<item>
<title>Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering</title>
<link>https://6ix.com/company/apogee-therapeutics-inc-common-stock/news/apogee-therapeutics-inc-announces-proposed-underwritten-public-offering-2025-10-08</link>
<guid isPermaLink="true">https://6ix.com/company/apogee-therapeutics-inc-common-stock/news/apogee-therapeutics-inc-announces-proposed-underwritten-public-offering-2025-10-08</guid>
<pubDate>Wed, 08 Oct 2025 04:00:00 GMT</pubDate>
<description>SAN FRANCISCO and BOSTON, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing</description>
</item>
<item>
<title>Apogee Therapeutics, Inc. Announces Pricing of $300 Million Underwritten Public Offering</title>
<link>https://6ix.com/company/apogee-therapeutics-inc-common-stock/news/apogee-therapeutics-inc-announces-pricing-300-million-underwritten-public-offering</link>
<guid isPermaLink="true">https://6ix.com/company/apogee-therapeutics-inc-common-stock/news/apogee-therapeutics-inc-announces-pricing-300-million-underwritten-public-offering</guid>
<pubDate>Wed, 08 Oct 2025 04:00:00 GMT</pubDate>
<description>SAN FRANCISCO and BOSTON, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing</description>
</item>
<item>
<title>Apogee Therapeutics Announces Late-Breaker Presentation of 16-Week Data from Phase 2 APEX Trial of APG777 for Moderate-to-Severe Atopic Dermatitis at the Upcoming European Academy of Dermatology and Venereology (EADV) 2025 Congress</title>
<link>https://6ix.com/company/apogee-therapeutics-inc-common-stock/news/apogee-therapeutics-announces-late-breaker-presentation-16-week-data-phase-2-apex</link>
<guid isPermaLink="true">https://6ix.com/company/apogee-therapeutics-inc-common-stock/news/apogee-therapeutics-announces-late-breaker-presentation-16-week-data-phase-2-apex</guid>
<pubDate>Thu, 11 Sep 2025 04:00:00 GMT</pubDate>
<description>SAN FRANCISCO and BOSTON, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing</description>
</item>
<item>
<title>Apogee Therapeutics to Participate at the Stifel 2025 Virtual Immunology and Inflammation Forum</title>
<link>https://6ix.com/company/apogee-therapeutics-inc-common-stock/news/apogee-therapeutics-participate-stifel-2025-virtual-immunology-and-inflammation-forum</link>
<guid isPermaLink="true">https://6ix.com/company/apogee-therapeutics-inc-common-stock/news/apogee-therapeutics-participate-stifel-2025-virtual-immunology-and-inflammation-forum</guid>
<pubDate>Wed, 03 Sep 2025 04:00:00 GMT</pubDate>
<description>SAN FRANCISCO and BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), today announced that members of management will</description>
</item>
<item>
<title>Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/apogee-therapeutics-inc-common-stock/news/apogee-therapeutics-provides-pipeline-progress-and-reports-second-quarter-2025</link>
<guid isPermaLink="true">https://6ix.com/company/apogee-therapeutics-inc-common-stock/news/apogee-therapeutics-provides-pipeline-progress-and-reports-second-quarter-2025</guid>
<pubDate>Mon, 11 Aug 2025 04:00:00 GMT</pubDate>
<description>Positive 16-week data from APEX Phase 2 Part A met all primary and key secondary endpoints for APG777, a potentially best-in-class anti-IL-13 antibody, in</description>
</item>
<item>
<title>Apogee Therapeutics Announces Positive 16-Week Data from Phase 2 APEX Clinical Trial of APG777, its Potentially Best-in-Class Anti-IL-13 Antibody, in Moderate-to-Severe Atopic Dermatitis</title>
<link>https://6ix.com/company/apogee-therapeutics-inc-common-stock/news/apogee-therapeutics-announces-positive-16-week-data-phase-2-apex-clinical-trial</link>
<guid isPermaLink="true">https://6ix.com/company/apogee-therapeutics-inc-common-stock/news/apogee-therapeutics-announces-positive-16-week-data-phase-2-apex-clinical-trial</guid>
<pubDate>Mon, 07 Jul 2025 04:00:00 GMT</pubDate>
<description>APEX Part A met all primary and key secondary endpoints and exceeded trial objectives, including 71.0% decrease from baseline in EASI at Week 16 APG777</description>
</item>
</channel>
</rss>